Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for Melioidosis | Kisho | Kisho

Back to Melioidosis

Melioidosis — NIH Grants & Funding

Active and recent NIH-funded research on Melioidosis. Data from NIH RePORTER, last 36 months.

MONDO:0017775

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

Melioidosis has active NIH research funding with 15 funded grants totaling $14.5M.

15funded grants from NIH

Portfolio: $11.7MCumulative: $14.5M11 active4 completed10 PIs6 institutions

-64% YoY(FY2024 vs FY2025)

5 new grants started in the last 12 months.

By Research Theme

Translational

Basic Science

Biomarker / Dx

Epi / Nat. History

Funding by Fiscal Year

NIH fiscal year (Oct–Sep)

$4.5M

FY22

$2.1M

FY23

$5.5M

FY24

$2.0M

FY25

$507K

FY26

By Funding Mechanism

R21

N01

K01

K08

R01

R41

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Melioidosis. Strongest funded area: Translational / Drug Development. Largest gap: Translational / Drug Development.

Translational / Drug DevelopmentFunded, Few Publications

6 funded grants in Translational / Drug Development but only 1 related publication found for melioidosis. This may indicate early-stage research that hasn't yet produced published results.

Adjacent Research(3 grants)

These grants mention Melioidosis as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(3)

OtherF31Active

Identification of Cross-Protective Surface Antigens in Burkholderia Species

Badten, Alexander·UNIVERSITY OF TEXAS MED BR GALVESTON·GALVESTON, TX

$38,936 (FY2025)

NIH RePORTER

OtherR21Completed

Identification of novel anti-virulence compounds against Pathogenic Burkholderia

Schaefers, Matthew·BOSTON CHILDREN'S HOSPITAL·BOSTON, MA

$221,250 (FY2022)

NIH RePORTER

OtherF30Completed

Using new modalities of synthetic-lethal interactions to find alternative antibacterial drug targets

Zhang, Yifan·RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL·PISCATAWAY, NJ

$51,752 (FY2022)

NIH RePORTER

Kisho

Melioidosis — NIH Grants & Funding

Funding Landscape

By Research Theme

Funding by Fiscal Year

By Funding Mechanism

Funding Gap Analysis

Adjacent Research(3 grants)

Other(3)

Identification of Cross-Protective Surface Antigens in Burkholderia Species

Identification of novel anti-virulence compounds against Pathogenic Burkholderia

Using new modalities of synthetic-lethal interactions to find alternative antibacterial drug targets

Top Funded Institutions

Top Principal Investigators